Carney D N
Department of Medical Oncology, Mater Misericordiae Hospital, Dublin, Ireland.
Bull Cancer. 1987;74(5):495-500.
Detailed studies of both cell lines and fresh specimens of SCLC and NSCLC have demonstrated that considerable heterogeneity exists within each tumour with respect to morphology and the expression of a range of biomarkers. While retrospective studies suggest that the presence or absence of some of of some of these markers may be of clinical importance, future trials of lung cancer should assess these markers to determine their prospective value in predicting response to therapy, survival and cure from lung cancer.
对小细胞肺癌（SCLC）和非小细胞肺癌（NSCLC）的细胞系及新鲜标本进行的详细研究表明，每种肿瘤在形态和一系列生物标志物的表达方面存在相当大的异质性。虽然回顾性研究表明其中一些标志物的存在与否可能具有临床重要性，但未来的肺癌试验应评估这些标志物，以确定它们在预测治疗反应、生存率和肺癌治愈方面的前瞻性价值。
